pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

tarveda-therapeutics PRESS RELEASE ARCHIVE

Nov 1, 2021

Tarveda Therapeutics Announces Data from Phase 2 Trial of PEN-221 to Be Presented at NANETS 2021 Multidisciplinary NET Virtual Symposium

Oct 13, 2021

Tarveda Therapeutics to Present at Solebury Trout/BMO Private Company Showcase

Oct 13, 2021

Tarveda Therapeutics to Present at Solebury Trout/BMO Private Company Showcase

Sep 16, 2021

Tarveda Therapeutics and SciClone Pharmaceuticals Expand Partnership by Entering into a License Agreement for HSP90-PI3K Miniature Drug Conjugates in Greater China

Jun 4, 2021

Tarveda Therapeutics Presents Promising Phase 2 Data of PEN-221 in Gastrointestinal Mid-gut Neuroendocrine Tumors

May 20, 2021

Tarveda Therapeutics to Present Data from Phase 2 Study of PEN-221 at 2021 ASCO Annual Meeting

Sep 30, 2020

Tarveda Therapeutics Appoints Brian Roberts as Chief Executive Officer

Aug 4, 2020

Tarveda Therapeutics Publishes Preclinical Study Evaluating HSP90 Binding Miniature Drug Conjugate with Pan-PI3K Payload in Solid Tumors

Jul 30, 2020

Tarveda Therapeutics to Present at Upcoming Conferences

May 13, 2020

Tarveda Therapeutics Reports Complete Data from Phase 1 Portion of Phase 1/2a Study of PEN-866 to be Presented at the ASCO20 Virtual Scientific Program

Apr 27, 2020

Tarveda Therapeutics Presents Pharmacokinetic and Tumor Biopsy Data from First in Human Study of PEN-866 at the 2020 AACR Virtual Annual Meeting

Apr 21, 2020

Tarveda Therapeutics to Present Data from First in Human Study of PEN-866 at the 2020 AACR Virtual Annual Meeting

Apr 7, 2020

Tarveda Therapeutics Provides Update on Proposed Merger with Organovo

Apr 7, 2020

Organovo Announces Termination of Merger Agreement with Tarveda Therapeutics

Mar 19, 2020

Tarveda Therapeutics and SciClone Pharmaceuticals International Establish Licensing Agreement for PEN-866 in Greater China

Feb 25, 2020

Tarveda Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference

Jan 8, 2020

Tarveda Therapeutics to Present at the 2020 Biotech Showcase

Dec 16, 2019

Organovo and Tarveda Therapeutics Announce Definitive Merger Agreement

Oct 24, 2019

Tarveda Therapeutics Publishes Results of Preclinical Studies Evaluating PEN-221 as a Treatment for Small Cell Lung Cancer in Molecular Cancer Therapeutics

Sep 30, 2019

Tarveda Therapeutics Presents Data from the Phase 1 Portion of a Phase 1/2a Study of PEN-866 at the European Society for Medical Oncology (ESMO) Congress 2019

Sep 23, 2019

Tarveda Therapeutics to Present at Upcoming Conferences

Jun 11, 2019

Tarveda Therapeutics to Present at Raymond James Life Sciences and MedTech Conference

May 30, 2019

Tarveda Therapeutics Announces Presentation at 2019 BIO International Convention

Apr 3, 2019

Tarveda Therapeutics to Present at Needham and Company’s 18th Annual Healthcare Conference

Mar 26, 2019

Tarveda Therapeutics to Present Nonclinical Data on PEN-221 in Combination with Epigenetic Modulation at the 2019 AACR Annual Meeting

Mar 4, 2019

Tarveda Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference

Feb 4, 2019

Tarveda Therapeutics to Present at the 2019 BIO CEO and Investor Conference

Jan 4, 2019

Tarveda Therapeutics Provides Year-End Update

Jan 3, 2019

Tarveda Therapeutics to Present at the 2019 Biotech Showcase

Nov 8, 2018

Tarveda Therapeutics to Present at EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

Sep 26, 2018

Tarveda Therapeutics to Present at Cantor Fitzgerald 2018 Global Healthcare Conference

Sep 12, 2018

Tarveda Therapeutics Appoints Jeffrey Bloss, M.D. as Chief Medical Officer

Jun 4, 2018

Tarveda Therapeutics Announces Results from Phase 1 Study of PEN-221 Presented at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting

May 31, 2018

Tarveda Therapeutics to Present at Jefferies 2018 Global Healthcare Conference

May 29, 2018

Tarveda Therapeutics to Present at 2018 BIO International Convention

May 17, 2018

Tarveda Therapeutics to Present Data from Phase 1 Study of PEN-221 at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting

Apr 24, 2018

Tarveda Therapeutics Announces Dosing of First Patient in Phase 1/2a Study of PEN-866 for Patients with Solid Malignancies

Apr 18, 2018

Tarveda Therapeutics Presents Data Exploring the Efficacy of PEN-866 in Combination with PARP Inhibitors in Preclinical Models of Human Cancer at the AACR Annual Meeting 2018

Apr 17, 2018

Tarveda Therapeutics to Present Preclinical Data on PEN-866 in Combination with PARP Inhibitors at the 2018 AACR Annual Meeting

Apr 11, 2018

Tarveda Therapeutics to Present Preclinical Data on PEN-866 in Combination with PARP Inhibitors at the 2018 AACR Annual Meeting

Mar 6, 2018

Tarveda Therapeutics to Present at Upcoming Investor Conferences

Feb 5, 2018

Tarveda Therapeutics to Present at the 2018 BIO CEO and Investor Conference

Jan 4, 2018

Tarveda Therapeutics Appoints Brian Roberts as Chief Financial Officer

Jan 3, 2018

Tarveda Therapeutics Provides Year-End Update and Outlines Milestones for 2018

Dec 20, 2017

Tarveda Therapeutics to Present at the 2018 Biotech Showcase

Jun 19, 2017

Tarveda Therapeutics Appoints Biotech Business Veteran Michael A. Metzger to Board of Directors

Feb 2, 2017

Tarveda Therapeutics Raises $30 Million in Series D Financing to Advance Pentarin Miniaturized Drug Conjugates

Jan 5, 2017

Tarveda Therapeutics Provides Year-End Update and Outlines Milestones for 2017

Jan 4, 2017

Tarveda Therapeutics Announces Phase 1/2a Clinical Trial of PEN-221 Underway in Patients with Neuroendocrine Tumors and Small Cell Lung Cancer

Sep 19, 2016

Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License Agreement for HSP90 Drug Conjugate Oncology Platform

Feb 29, 2016

Tarveda Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference

Jan 27, 2016

Blend Therapeutics Secures $38 Million in Series C Financing led by Novo A/S and NEA and Changes Name to Tarveda Therapeutics

Jan 27, 2016

Tarveda Therapeutics Appoints Oncology Drug Development Leader Leila Alland, M.D., as Chief Medical Officer

Google Analytics Alternative